The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
|Videos|November 13, 2020
(AAO) Bringing high-level content to a virtual audience
Author(s)OT Staff Reports, David Hutton
Anne L. Coleman, MD, president of the American Academy of Ophthalmology, offers a preview of its virtual 2020 annual meeting. The AAO is rising to meet the challenges of staging a large-scale event in a virtual setting.
Advertisement
Anne L. Coleman, MD, president of the American Academy of Ophthalmology, offers a preview of its virtual 2020 annual meeting. The AAO is rising to meet the challenges of staging a large-scale event in a virtual setting.
Advertisement
Related to this article
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
5